Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402045 | 1.00 | NPSR1 (0.41) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25302428 | 0.91 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2ATMKDM4EMEN1 | |
| SCHEMBL29402377 | 0.91 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2ATMKDM4EMEN1 | |
| SCHEMBL29403919 | 0.90 | ATM (0.44) | ALDH1A1SMN1; SMN2ATMKDM4EMEN1 | |
| SCHEMBL25299914 | 0.90 | ATM (0.44) | ALDH1A1SMN1; SMN2ATMKDM4EMEN1 | |
| SCHEMBL25255387 | 0.84 | PDE4A (0.47) | ALDH1A1ATMKDM4EMEN1KMT2A | |
| SCHEMBL29404573 | 0.84 | PDE4A (0.47) | ALDH1A1ATMKDM4EMEN1KMT2A | |
| SCHEMBL25301767 | 0.83 | KMT2A (0.41) | NPSR1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL25257051 | 0.81 | RXFP1 (0.39) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30253418 | 0.81 | RXFP1 (0.39) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | LMITO THERAPEUTICS INC. (KR) | 2024-02-01 | — | — | US | disclosed |
| EP-4212530-A1 | IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | Lmito Therapeutics Inc. (KR) | 2023-07-19 | — | — | EP | disclosed |
| CN-115956071-A | Imidazoquinoline or benzindazolone compounds and intermediates for their preparation | LMITO药业株式会社 | 2023-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034719-A1 | IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME | NQO1, NFE2L2, KEAP1 | NPSR1 4198/4885CYP1A2 100/4885CYP3A4 111/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | NPSR1 2859/4885CYP1A2 114/4885CYP3A4 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.